These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 25557586

  • 1. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.
    Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L.
    Am J Hematol; 2015 Apr; 90(4):301-5. PubMed ID: 25557586
    [Abstract] [Full Text] [Related]

  • 2. Pharmacoepidemiology of Immune Thrombocytopenia: protocols of FAITH and CARMEN studies.
    Moulis G, Sailler L, Adoue D, Lapeyre-Mestre M.
    Therapie; 2014 Apr; 69(5):437-48. PubMed ID: 25285364
    [Abstract] [Full Text] [Related]

  • 3. Risk infection to spare bleeding? The quandary of splenectomy for immune thrombocytopenia.
    Zeller M, Arnold DM.
    Am J Hematol; 2015 Apr; 90(4):271-2. PubMed ID: 25677795
    [No Abstract] [Full Text] [Related]

  • 4. Prevalence of pneumococcal vaccination in adult immune thrombocytopenia patients exposed to rituximab or to splenectomy.
    Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Adoue D.
    Eur J Haematol; 2013 May; 90(5):438-9. PubMed ID: 23444912
    [No Abstract] [Full Text] [Related]

  • 5. Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect.
    Moulis G, Lapeyre-Mestre M, Palmaro A, Sailler L.
    J Thromb Haemost; 2017 Apr; 15(4):785-791. PubMed ID: 28078756
    [Abstract] [Full Text] [Related]

  • 6. ITP and international guidelines: what do we know, what do we need?
    Rodeghiero F, Ruggeri M.
    Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
    [Abstract] [Full Text] [Related]

  • 7. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study.
    Moulis G, Lapeyre-Mestre M, Montastruc JL, Sailler L.
    Autoimmun Rev; 2015 Feb; 14(2):168-73. PubMed ID: 25461471
    [Abstract] [Full Text] [Related]

  • 8. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.
    Auger S, Duny Y, Rossi JF, Quittet P.
    Br J Haematol; 2012 Aug; 158(3):386-98. PubMed ID: 22612239
    [Abstract] [Full Text] [Related]

  • 9. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
    Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA, RITP study group.
    Lancet; 2015 Apr 25; 385(9978):1653-61. PubMed ID: 25662413
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R.
    Am J Hematol; 2012 Sep 25; 87(9):886-9. PubMed ID: 22718483
    [Abstract] [Full Text] [Related]

  • 11. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
    Routy B, Boulassel MR, Spurll GM, Warner MN, Routy JP.
    Am J Ther; 2013 Sep 25; 20(2):219-22. PubMed ID: 23466621
    [Abstract] [Full Text] [Related]

  • 12. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.
    Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Derumeaux H, Adoue D.
    Am J Hematol; 2014 Jan 25; 89(1):41-6. PubMed ID: 24038066
    [Abstract] [Full Text] [Related]

  • 13. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab].
    Toubi E.
    Harefuah; 2012 Nov 25; 151(11):620-1, 655. PubMed ID: 23367731
    [Abstract] [Full Text] [Related]

  • 14. Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012.
    Michel M, Suzan F, Adoue D, Bordessoule D, Marolleau JP, Viallard JF, Godeau B.
    Br J Haematol; 2015 Jul 25; 170(2):218-22. PubMed ID: 25824587
    [Abstract] [Full Text] [Related]

  • 15. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.
    Br J Haematol; 2014 Oct 25; 167(2):243-51. PubMed ID: 25041261
    [Abstract] [Full Text] [Related]

  • 16. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C, Reu FJ, Ho AD, Hensel M.
    Ann Hematol; 2007 Oct 25; 86(10):711-7. PubMed ID: 17622529
    [Abstract] [Full Text] [Related]

  • 17. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma.
    Landgren O, Björkholm M, Konradsen HB, Söderqvist M, Nilsson B, Gustavsson A, Axdorph U, Kalin M, Grimfors G.
    J Intern Med; 2004 Jun 25; 255(6):664-73. PubMed ID: 15147530
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.
    J Intern Med; 2009 Nov 25; 266(5):484-91. PubMed ID: 19549092
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.